Pharmaceutical

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.

May 25, 2024 - 04:00
ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
Read the original article

Tags:

Previous Article

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

Next Article

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar

CymaBay maps out regulatory filing for primary biliary ...

Sep 21, 2023

Opinion: New federal guidance is hurting cancer patients, especially those in rural areas

Opinion: New federal guidance is hurting cancer patient...

Mar 2, 2024

iOnctura expands PI3K inhibitor programme to NSCLC

iOnctura expands PI3K inhibitor programme to NSCLC

Jul 10, 2024